Polycythemia Vera (PV) in 2025: Competition and Evolving Treatment Options

The treatment landscape for Polycythemia Vera (PV) in 2025 is rapidly evolving, driven by the entry of new drugs, uncertainties around generics, and shifting pricing strategies.

Jakafi Generics: Delayed Competition?

Jakafi, one of the most widely used therapies for Polycythemia Vera, was expected to face generic rivals following its patent expiration. However, recent signals suggest a potential delay in the introduction of generics, giving Incyte extended market protection. This prolongs the ongoing discussion of Jakafi vs Besremi, where physicians must weigh both cost and treatment convenience when choosing between the two.

Besremi Expands its Role in PV Care

PharmaEssentia’s Besremi (ropeginterferon alfa-2b) has firmly established its presence, with inclusion in NCCN guidelines boosting its recognition among hematologists. Its long-acting dosing provides an edge over daily therapies, though concerns around Besremi side effects and the Besremi annual cost remain significant hurdles. Across Europe, prices fluctuate—referred to as Besremi prix, Besremi τιμη, and Besremi preis—while the U.S. Besremi price often stands higher, shaping both patient and physician decisions.

Rusfertide: A Game-Changer in the Making?

Protagonist Therapeutics is advancing Rusfertide polycythemia vera treatment, a novel hepcidin mimetic injection showing promise in controlling hematocrit. While its FDA approval is still pending, expectations remain high. Yet, concerns linger around Rusfertide price, Rusfertide side effects, and global affordability (such as Rusfertide cost in India). Investors were surprised by the early withdrawal of Rusfertide’s Breakthrough Therapy Designation (BTD), but optimism continues as experts closely watch when will Rusfertide be available.

Market Dynamics in 2025

With therapies like Jakafi, Besremi, and Rusfertide competing for share, cost considerations will play a decisive role in prescribing trends. Factors such as Jakafi cost, real-world Besremi reviews, and the ultimate Rusfertide price will strongly impact patient access. Meanwhile, regional debates—such as Besremi vs hydroxyurea and Besremi oder Jakavi in Europe—highlight how practice patterns differ across markets.

Looking Ahead

As Besremi for Polycythemia Vera continues to strengthen its foothold, and the industry eagerly awaits clarity on when will Rusfertide be available, the Polycythemia Vera (PV) in 2025 treatment landscape is set for intense and dynamic competition.